Teva Pharmaceutical Industries priced $4.9 billion in senior notes to fund redemptions and general c

Vea los precios de cotización de acciones de ADR TEVA patrocinado por Teva Pharmaceutical Industries Limited, información financiera, pronósticos en tiempo real y noticias de la compañía de CNN.

Leerink Partners initiated coverage on Teva Pharmaceutical Industries in a report on Wednesday. They set an "outperform" rating and a $45.00 price target for the company.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 997,617 shar

Compass Financial Management LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 32,254 shares of the company

Teva Pharmaceutical Industries recently reported positive topline results from a Phase 2a trial of its anti‑IL‑15 antibody TEV ‘408 in adults with celiac disease, meeting the primary endpoint of preventing gluten‑induced intestinal damage with a favorable safety profile. With no approved drug treatments for celiac disease today and Royalty Pharma committing US$500 million to accelerate TEV ‘408’s development, this program highlights Teva’s potential “pipeline‑in‑a‑product” opportunity beyond...

Nykredit A S purchased a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 443,442 shares of the company

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rat

UBS Group upped their price target on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Friday.